This review looks at how important molecular drivers, like metabolic changes caused by IDH1/2 mutations, MGMT promoter methylation status, receptor tyrosine kinase signaling involving EGFR and EGFRvIII, and changes in epigenetics seen in H3 K27M, are creating new opportunities in immunotherapy, CAR-T cell therapy, prec...
Joaquin Fiallo Arroyo, Jose E. Leon-Rojas· Biomedicines· 0 citations
Glioblastoma (GBM) remains one of the most lethal and intractable central nervous system malignancies, characterized by aggressive cellular proliferation, profound hypoxia, and an immunosuppressive microenvironment. The primary pharmacokinetic obstacle for systemic interventions is the blood–brain barrier (BBB), which...
Joaquin Fiallo Arroyo, Bernardo Castellón, Jose E. Leon-Rojas· International Journal of Mol...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.